2026-04-18T00:32:22Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4741632025-08-31T17:00:27Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Notario Rincón, Lucía author Cucurull, Marc author Cerdà, Gabriela author Sanz, Carolina author Carcereny, Enric author Muñoz-Mármol, Ana author Hernández, Ainhoa author Domènech, Marta author Morán, Teresa author Sanchez-Cespedes, Montse author Costa, Marta author Mate, Jose Luis author Esteve, Anna author Saigí, Maria author 2023 Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. Among all patients included, 47% carried KRAS G12C mutation whereas 53% harbored KRAS non-G12C mutations. PD-L1 status was available for 77% of cases, with higher expression among KRAS G12C tumors (p = 0.01). Better overall survival and progression-free survival were observed in high PD-L1 expression tumors, regardless of KRAS mutation type. The heterogeneous nature of KRAS-mutant tumors and the presence of other co-mutations may contribute to different outcomes to immunotherapy-based strategies. Non-small cell lung cancer Lung adenocarcinoma KRAS PD-L1 Immunotherapy Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy : differences according to KRAS G12C vs. non-G12C